Baudax Bio Inc. is a pharmaceutical company. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. Baudax Bio Inc. is based in Malvern, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $1.27M |
| Net Income (Most Recent Fiscal Year) | $-58.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 52.46M |
| Free Float | 52.41M |
| Market Capitalization | $0.01M |
| Average Volume (Last 20 Days) | 2388.33 |
| Beta (Past 60 Months) | 0.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.55% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |